

## Peptide receptor radionuclide therapy (PRRT) in radioiodine-refractory thyroid cancer: A case report of significant response to Lu177 DOTA-TATE treatment

DOI: 10.20945/2359-3997000000451

Arch Endocrinol Metab. 2022;66(2):269-71

Where you read:

**Mohammad Esmatinia<sup>1</sup>**  
<https://orcid.org/0000-0001-8582-5658>

Should read:

**Mahdi Mottaghi<sup>1</sup>**  
<https://orcid.org/0000-0001-8582-5658>

DOI: 10.20945/2359-39970000000520

Arch Endocrinol Metab. 2022;66/4

